BXPHARMA Beximco Pharmaceuticals Limited
Pharmaceuticals & Chemicals
Tk 143.5 as of 2026-11-12 14:09:02
Data completeness 100%
Score breakdown
Weights: consistency 30%, profitability 30%, solvency 20%, valuation 20%; then risk flags add or subtract points. Full method
Why this score
Strengths
- Consistency Paid a dividend every year (5/5)
- Profitability Net profit growing 13.48% a year
- Solvency Low debt: debt/equity 0.1x (below 0.5)
- Valuation P/E 7.11 is low (general benchmark ≤ 12)
- Valuation Trades near book value (P/NAV 1.03x)
- Valuation Price is 43% below the Graham fair value (Tk 251.3)
- Ownership Institutions (25.79%) hold more than the public (17.12%)
Notes
- Consistency EPS rose in 2 of 4 years (mixed)
- Profitability Average ROE 12.66% (moderate)
Risk flags
No flags raised.
Valuation
52-week range
44.2% above the low, 9.5% below the high. Near the low is only interesting if profit is intact (see concerns above) and the fall has a temporary cause.
Quality and growth
Dividends and safety
Size, liquidity and ownership
Shareholding
- Sponsor/director 30.1%
- Institution 25.8%
- Foreign 27%
- Public 17.1%
Audited history
| Year | EPS (Tk) | NAV/share | Net profit (cr) | Cash div % | Bonus % |
|---|---|---|---|---|---|
| 2020 | 8.67 | 80.12 | 351 | 15 | 10 |
| 2021 | 11.49 | 83.01 | 513 | 35 | 0 |
| 2022 | 11.2 | 91.01 | 500 | 35 | 0 |
| 2023 | 10.34 | 97.91 | 461 | 35 | 0 |
| 2024 | 13.07 | 107.48 | 583 | 40 | 0 |
Fiscal year ends June. EPS, NAV and profit are as audited by the company and published by DSE. Financials last fetched: 14/11/2026.
Shariah screen (partial)
Business screen and the debt ratio (loans / market cap 9.4%, limit 33%) are automated. Interest income (under 5% of revenue) and cash/investment ratios must be checked in the annual report.
Educational, not investment advice. Verify on DSE and StockNow before making any decision.